A comparison of COVID-19 inpatients by HIV status

Sarah Flannery1, Rebecca Schwartz2, Rehana Rasul3

  • 1Division of Infectious Diseases, Department of Medicine, 232890Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, USA.

Insights

People living with HIV (PLWH) hospitalized with COVID-19 had similar outcomes to HIV-negative patients. However, PLWH with low CD4 counts or off HIV treatment faced higher mortality, while IL-6 inhibitors showed a protective effect.

Area of Science:

  • Infectious Diseases
  • Virology
  • Public Health

Background:

  • Early COVID-19 pandemic disproportionately affected New York City.
  • People living with HIV (PLWH) represent a vulnerable population with potential comorbidities.
  • Understanding COVID-19 outcomes in PLWH is crucial for targeted healthcare strategies.

Purpose of the Study:

  • To compare in-hospital morbidity and mortality of COVID-19 patients with and without HIV.
  • To identify risk factors for adverse outcomes among hospitalized PLWH with COVID-19.
  • To evaluate the impact of specific treatments on COVID-19 outcomes in PLWH.

Main Methods:

  • Retrospective cohort study comparing COVID-19 inpatients with and without HIV.
  • Analysis of demographic, clinical, and treatment data.
  • Statistical comparison of in-hospital mortality, ICU admission, and ventilator use.

Main Results:

  • No significant difference in ventilator use, ICU admission, or in-hospital mortality between PLWH and HIV-negative patients.
  • PLWH were younger, with higher prevalence of male sex, Black race, malignancies, and chronic liver/renal disease.
  • Among PLWH, viral unsuppression, low CD4% (<14), and not being on HIV treatment were associated with higher mortality.
  • IL-6 inhibitors were associated with lower mortality in PLWH.
  • Certain medications (antifungals, hydroxychloroquine, azithromycin, steroids, vasopressors) were linked to higher mortality in PLWH.

Conclusions:

  • Hospitalized COVID-19 patients with HIV do not experience worse outcomes than the general population.
  • Specific subgroups of PLWH, including those with low CD4 counts or off HIV treatment, are at increased risk.
  • IL-6 inhibitors may improve outcomes for PLWH with COVID-19.
  • Further research is needed to clarify the role of various medications in COVID-19 outcomes for PLWH.

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
519
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
47.9K
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
440